FindTrial
Sign In

Correction of vitamin D deficiency in chronic hepatitis C patients and effect on cytokines responses related to liver fibrotic pathway: A Randomized Double-Blind Placebo Control Study

Correction of vitamin D deficiency in chronic hepatitis C patients and effect on cytokines responses related to liver fibrotic pathway: A Randomized Double-Blind Placebo Control Study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20161103003
Enrollment
58
Registered
2016-11-03
Start date
2014-11-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C patient liver fibrosis&#44

Interventions

Ergocalciferol (D2) 20&#44
000 IU/ tab,Placebo tablet
Active Comparator Drug,Placebo Comparator Drug
Vitamin D group,Placebo group

Sponsors

The Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn University
Lead Sponsor
The Ratchadapiseksompotch Fund&#44
Collaborator
Faculty of Medicine&#44
Collaborator
Chulalongkorn University
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Chronic hepatitis c or CHC cirrhosis child A 2. 25&#45;OH vitamin D < 30 ng/ml

Exclusion criteria

Exclusion criteria: 1. HIV&#44; DM&#44; chronic lung disease 2. other cause of chronic hepatitis 3. preganancy 4. active bacterial infection 5. immunosuppresive drug 6. GFR < 60

Design outcomes

Primary

MeasureTime frame
matrixmetalloprotinase &#45; 9 6 weeks after end of intervention Blood serum change—

Secondary

MeasureTime frame
PDGF&#44; TIMP1&#44; IL22 and IFN&#45;γ 6 weeks after end of intervention Blood serum change—

Countries

thailand

Contacts

Public Contactpiyawat komolmit

Chulalongkorn unoversity

namon_82@hotmail.com02-256-4356

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026